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anti-adhesive, angiogenic, vasodilative and many other properties 
of polyphenols have been found out, which are implemented mainly 
through effects on molecular targets of intracellular cascades [4].
One of the representatives of the plant polyphenol is phytoalexin 
resveratrol (3,4,5-trihydroxy-trans-stilbene) found in more than 30 
kinds of plants and used in medicine as a natural extract and synthetic 
drug [5]. Resveratrol has a direct antiradical action by means of three 
hydroxyl groups in its chemical formula, regulates the activity of 
enzymes of cyclooxygenase (COX) and lipoxygenase (LOX), has anti-
inflammatory activity-it inhibits the pathogenic effect of a key factor 
of activating process of inflammation of NF-kB through inhibition 
of IkB-kinase α (IKKα), and has endothelio protective effect through 
activation of endothelial synthetase of nitric oxide (eNOS) as well [6-8].
The aim of our research was to study the effects of resveratrol on 
the CSI indicators in stable CHD.
Materials and methods
The study involved 85 people of both sexes (36 females and 49 males) 
aged 48–67, diagnosed with CHD, stable angina pectoris, FC II, НF 
0-І, the average risk. The selection of patients was carried out using an 
objective and instrumental examination: Rose angina questionnaires, 
SCORE table, bicycle ergometer and Doppler echocardiography. 
Every patient gave a written informed consent to participate in the 
research, according to the requirements of the Declaration of Helsinki. 
The criterion for inclusion into the study was signs of coronary 
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Abstract
This study aimed to investigate the effects of plant polyphenol of resveratrol on chronic systemic inflammation indicators of stable coronary artery disease. 85 patients 
with coronary heart disease were recruited and prescribed a standard therapy (β-blockers, statins, aspirin). 30 patients received resveratrol at a dose of 100 mg daily 
and the other serves as the control group. Cytokines and the expression of mRNA gene of inhibitor of kappa B α (IkBα) of nuclear factor of transcription kappa 
B (NF-kB) were determined. The results show that patients with coronary artery disease exhibited increased levels of interleukin-1β (IL-1β), tumor necrosis factor 
(TNFα), and IL-10 in the blood. Resveratrol treatment led to a reliable reduction IL-1β and TNFα, the content of IL-10 tended to reduce. In addition, we failed 
to notice any significant difference in the inhibitor of kappa B α (IkBα) of nuclear factor of transcription kappa B between groups.  In conclusion, in patients with 
coronary artery disease, resveratrol shows anti-inflammatory properties via reducing the content of proinflammatory cytokines in the blood, such as IL-1β and TNFα.
Abbreviations and symbols: CSI: Chronic systemic inflam-
mation; CHD: Coronary heart disease; CK: Cytokines; TNFα: Tumor 
necrosis factor; IL-1β: Interleukin-1β; IL-10: Interleukin-10; IkBα: In-
hibitor of kappa B α; NF-kB: Nuclear factor of transcription kappa B; 
Real-time PCR: Polymerase chain reaction in real time; ASVD: Ath-
erosclerosis; ET: Vascular endothelium; COX: Cyclooxygenase; LOX: 
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scale; SIRT1: Sirtuin 1; NO: Nitric oxide; EMP: Circulating endothelial 
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Introduction
Atherosclerosis (ASVD) has been still relevant and unsolved 
problem of clinical medicine. Coronary heart disease (CHD), which 
morphological basis is ASVD, heads the list of the top 10 causes of 
death in the world and is accounted for 12.8%. In Ukraine, CHD is 
among leading causes of cardiovascular mortality (68.8%) [1].
Chronic systemic inflammation (CSI) is the pathogenetic basis of 
ASVD. Under the influence of damaging factors, such as free radicals, 
endo- and exotoxins, high blood pressure, etc., vascular endothelium 
(ET) is activated with the development of its systemic dysfunction: 
functioning molecular signaling cascades with increased synthesis of 
proinflammatory cytokines (CK) and adhesion molecules is enhanced, 
the transmembrane transport and regulation of vascular tone are 
disrupted [2]. These data substantiate the relevance of active search for 
CSI correction agents at ASVD in order to improve treatment.
Recently, researchers attention has been drawn to the polyphenolic 
compounds of plant origin. Polyphenols possess hydrophilic 
properties and play the role of free radical scavengers, which lead to 
their antioxidant effect. They also activate paraoxonase in the blood 
promoting hydrolysis of hydroperoxides [3]. Anti-inflammatory, 
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heart disease: stable angina pectoris, FC II. Exclusion criteria were 
the presence of Stage 2 heart failure (HF), Stage 2 hypertension, 
concomitant chronic diseases of bronchopulmonary system, liver and 
kidney dysfunction, endocrine or allergic disorders, diseases of the 
musculoskeletal system in the acute stage, cancer, thrombophlebitis. 
Bicycle ergometer was used with a continuously increasing step-by-step 
protocol of dosed physical load with duration of one stage of 2 minutes, 
the test was considered to be “positive” in the case of occurrence of 
objective evidence of myocardial ischemia during the trial. Every 
patient completed a load capacity of 75 W, which corresponded to 
FC II. The presence of heart failure (HF) syndrome was established by 
clinical data and results of Doppler echocardiography. In the presence 
of clinical symptoms (shortness of breath with exertion, palpitations, 
fatigue) and decrease in left ventricular ejection fraction (LVEF), the 
diagnosis of HF was established. 43% of CHD patients had LVEF values 
of 45–50%, corresponding to the degree of heart failure of Stage 1 with 
preserved systolic function, and the rest had ejection fraction greater 
than 50%. All the patients showed signs of diastolic dysfunction of the 
left ventricle with impaired relaxation (Type 1). The degree of risk was 
being determined by the total assessment using SCORE table and LVEF 
values that in all patients of study groups was less than 3% of annual 
mortality risk (the average level) [9]. Every patient was prescribed a 
standard CHD therapy: along with recommendations for lifestyle (diet 
therapy, dosed physical exertion, smoking cessation), beta-blockers 
(5 mg of bisoprolol once a day in the morning), statins (10 mg of 
atorvastatin once a day at bedtime) and 75 mg of aspirin at bedtime 
were prescribed. After stabilization of the clinical course of CHD 
in a month after the basic treatment patients were divided into the 
study group (30 people) and comparison ones (55 people) by random 
sampling and examining with clinical and laboratory methods.
For objectification of patients’ condition the Health-Related 
Quality of Life Questionnaire 3 level version (EQ-5D-3L) with the 
estimation of EQ-5D index and visual analogue scale (EQ-5D-VAS) 
data analysis were used [10]. 
To assess the level of CSI, the level of cytokines (i.e. tumor necrosis 
factor (TNFα), interleukin-1β (IL-1β), and IL-10) in the blood was 
determined via immunoenzymatic method using the test system 
“Vector-Best” (Novosibirsk) based on the solid-phase “sandwich”–
variant of immunoenzymatic analysis with mono- and polyclonal 
antibodies [11]. The expression of the gene of inhibitor of kappa B 
α (IkBα) in peripheral blood mononuclear cells was determined by 
polymerase chain reaction in real time (real-time PCR) using the DT 
Light DNA amplifier (“DNA Technology”, Russia) [12]. To obtain 
cDNA, a set of reagents for the reaction of inverse transcription 
(SYNTOL, Russia) was used. The total RNA was isolated from biological 
sample using the reagent set “RIBO-zol-B” (AmpliSens, Russia). 
The sequence of primers for determining IkBα gene expression-F: 
5’–GGC TGA AGA AGG AGC GGC TA–3’, R: 5’–CCA TCT GCT 
CGT ACT CCT CG–3’. Amplification mode: 95.0–5 minutes–1 cycle; 
62.0–40 seconds, 95.0–15 seconds–40 cycles. As a reference gene the 
“housekeeping” gene GAPDH was used. For data analysis a relative Сt 
method of calculation by the formula 2-∆Сt and 2-∆∆Сt was applied.
After the examination of patients of the research group they were 
additionally prescribed resveratrol at a dose of 100 mg once daily per os 
on the background of basic therapy; the comparison group continued 
taking basic therapy. The results of treatment were evaluated after 2 
months by re-examination in the above mentioned amount. During 
the examination and treatment of patients any complications, allergic 
reactions or hypersensitivity to medicines were not found.
Statistical analysis of the results of the research was carried out 
using KyPlot program. The hypothesis of normal distribution was 
checked by Shapiro-Wilk test. When comparing these study groups 
before and after treatment, paired Student’s t-test was used, for 
inappropriate distribution-Wilcoxon signed-rank test and Steel test for 
paired observations. When comparing data between groups, unpaired 
Student’s t-test and Steel-Dwass test (nonparametric analogue of 
Tukey’s range test) were used. Search for relations between variables 
was held using Pearson`s correlation or, subject to maldistribution, 
Spearman`s and Kendall`s rank correlation. Data of statistical analysis 
were presented in the form of X ± σ, where X is an average value, σ 
is an average square deviation. Due to improper distribution and 
characteristics of discontinuous series the data were given as Me (Q1-
Q3), where Me is a median, Q1 and Q3 are the first and third quartiles. 
Data differences were considered to be significant at a level of p<0.05 
[13].
Results and discussion
Mean EQ-5D-index before treatment in patients with coronary 
artery disease was 0.738 ± 0.061, EQ-5D-VAS–55.63 ± 5.38. After 2 
months of treatment patients treated with resveratrol more often 
than the comparison group patients noted the appearance of vitality, 
efficiency improving, reducing the number and duration of episodes of 
pain in the heart. EQ-5D-index (p<0.001) and values by EQ-5D-VAS 
scale (p<0.001) decreased. In the comparison group EQ-5D-index also 
decreased (<0.001) after treatment, EQ-5D-VAS did not significantly 
change (p > 0.05). Data of EQ-5D questionnaire have been shown on 
Figure 1.
Patients with coronary artery disease have shown an increased 
content of ІL-1β (9.76 ± 3.33 pg/mL) (in healthy people–1.6 
(confidence interval–0-11 pg/mL)), TNFα (9.11 ± 2.43 pg/mL) (in 
healthy people–0.5 (0-6) pg/mL), IL-10 content was 10.97 ± 2.97 pg/
mL (in healthy people–5 (0-31) pg/mL), corresponding with modern 
scientific data on changes in the CK level in terms of atherogenesis 
[2,14]. IL-1β and TNFα are one of the leading mediators of 
inflammatory response, inducing production of proinflammatory 
CK, chemoattractants, adhesion molecules, growth factors through 
increasing the transcriptional activity of NF-kB.
Figure 1. Dynamics of subjective status of patients according to the questionnaire EQ-
5D-3L [*: Reliable difference between indicators before and after treatment; A: Group of 
comparison; B: Group of investigation (resveratrol)].
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After 2 months of therapy with resveratrol in patients there was 
a decrease of the level of CK (IL-1β and TNFα), and the tendency to 
lower levels of IL-10 (0.05>р<0.1) was noted (Table 1). However, in 
the comparison group presumable changes in the levels of the CK 
were not found, despite the statements on anti-inflammatory effect 
of statins [15]. Perhaps for pleiotropic anti-inflammatory effect larger 
therapeutic doses of statins are necessary, but with building-up a dose 
the probability of complications increases, especially in chronic forms 
of coronary artery disease (according to large-scale studies TNT, 
IDEAL) [16]. Therefore, the combination of statins with resveratrol 
can afford to get the necessary pathogenetically valid therapeutic effect 
on the ability to titrate the dose of statins, focusing exclusively on the 
blood lipid spectrum and levels of transaminases with guaranteed 
anti-inflammatory effect from the lowest doses due to the combined 
potential effect of these drugs.
Recent scientific studies have shown that effectiveness of resveratrol 
to reduce the level of inflammatory CK is implemented by several 
mechanisms: by direct antioxidant action as free radical scavenger due 
to the presence of OH-groups, by activation of catalase, superoxide 
dismutase, increased levels of glutathione transferase, peroxidase and 
reductase, decreased activity of COX and LOX, regulation of nitric 
oxide (NO) synthesis, increased expression level of protein sirtuin 
1 (SIRT1) providing density of histone backbone and preventing 
activation of ІККα [17,18]. IKKα subunit has the greatest importance 
in the structure of the IKK because being activated it destroys IkBα 
connection with the dimmer NF-kB (p50/p65). NF-kB р65 (Rel 
A) subunit, which is the gene transcription factor of molecules of 
inflammatory response, is translocated into the nucleus [19]. Each 
of these mechanisms can contribute to our results of reducing IL-
1β and TNFα under the influence of resveratrol. It has been proven 
that inactivation of NF-kB does not affect IL-10 expression processes, 
which can be an explanation for no reduction of CK in our study [20].
In patients treated with resveratrol, as in the comparison group, the 
expression of mRNA IkBα in blood mononuclear cells did not change 
significantly (p=0.441 and p=0.570 respectively). IkBα retains NF-kB in 
an inactive state in the cytosol of cells, preventing the transcription of 
inflammatory molecules. Reduced synthesis of proinflammatory CK in 
our study could be achieved by other mechanisms of resveratrol action, 
such as antioxidant one or activation of SIRT1 (Table 2).
The revealed ability of resveratrol to reduce the content of 
EMP CD32+CD40+ demonstrates its anti-inflammatory and 
endothelioprotective properties [21]. It is known that increasing the 
number of EMP is the evidence of ET dysfunction. Predominant cause 
of this increasing may be determined by definition of the expression 
of appropriate molecules. Thus, for EMP of apoptotic endotheliocytes 
typical are CD31 and CD105 markers, for EMP, forming activated 
endotheliocytes,-CD32 (FcγRII), CD40 (TNFRSF5), CD54 (ICAM-1), 
СD62 (E та Р), СD64 (FCGR1B), CD146 markers [22]. Inflammatory 
activation of ET, which marker is EMP CD32+CD40+ studied, is 
considered to be an essential component of atherogenesis [23]. 
Arguably, resveratrol acts on one of the above-mentioned 
mechanisms inhibiting proinflammatory signal transduction. 
According to scientific data, inhibition of STAT1 (transcription 
activator transmitting a signal–1) or IRF-1 (factor regulating interferon 
1), but not NF-kB, inhibits the expression of CD40 molecule at mRNA 
and protein level [24,25]. Despite the lack of probable reduction of 
mRNA IkBα expression under resveratrol in our study, a positive effect 
of resveratrol on levels of proinflammatory CK has been found out. 
In our opinion, inhibition of STAT1 or IRF-1 may also be one of the 
possible mechanisms of its action [26].
Conclusions
The intake of resveratrol in patients with stable coronary heart 
disease reveals a positive impact on the level of systemic inflammation 
during two-month treatment, unlike statins (atorvastatin) as a means 
of basic therapy. Along with improved clinical course, according 
to the EQ-5D questionnaire, resveratrol reduces the levels of 
proinflammatory CK IL-1β and TNFα, but the impact of resveratrol on 
the ІkВα expression at mRNA level has not been revealed. Mechanisms 
of anti-inflammatory activity of resveratrol are multimodal and cause 
CSI correction involving different signaling cascades. Taking into 
account proven anti-inflammatory effect by endpoints of assessment 
of the inflammatory response level, resveratrol should be considered 
as effective pathogenetically reasonable treatment for ASVD and 
coronary artery disease.
Group /Mark Statistical Index TNFα, pg/ml IL-1β, pg/ml IL-10, pg/ml
Before therapy After therapy Before therapy After therapy Before therapy After therapy
Group of comparison Х 8.53 8.34 9.46 7.16 10.51 8.72
σ +3.24 +2.17 +2.98 +2.98 +3.33 +3.51
 р=0.866 р=0.127 р=0.134
Group of investigation (resveratrol) Х 9.69 7.28 10.05 6.98 11.41 9.39 
σ +1.63 +2.18 +3.67 +2.52 +2.61 +3.06
 р=0.013 р=0.002 р=0.055
X: The sample mean; σ: Standard deviation; p: The probability
Table 1. Cytokines levels in the blood serum of the subjects of the study.
Group / Mark Statistical 
index
Group of comparison Group of investigation (resveratrol) 
  Before treatment After treatment Before treatment After treatment
 
Expression mRNA IkBα. 2-ΔСt
 
Х 0.0234 0.0253 0.0246 0.0220 
σ ±0.0198 ±0.0155 ±0.0131 ±0.0092
p 0.570 0.441
2-ΔΔСt Х 0.120                    -0.142 
(min:max) (-2.64:+2.83) (-2.0:+1.87)
X: The sample mean, σ: Standard quadratic deviation, (min:max): Extreme value variation series; p: The probability; *: Significant differences with the data of all groups before and after 
treatment (р<0.01)
Table 2.  Level of mRNA IkBα expression in peripheral blood mononuclear cells of the subjects of the study.
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